The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis

Br J Haematol. 2017 Aug;178(4):645-646. doi: 10.1111/bjh.14162. Epub 2016 Jun 13.

Authors

Mikhail Fominykh¹, Vasily Shuvaev¹, Irina Martynkevich¹, Lyubov Polushkina¹, Vera Udaleva¹, Kudrat Abdulkadyrov¹

Affiliation

¹ Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia.

PMID: 27291991
DOI: 10.1111/bjh.14162

No abstract available

Keywords: Ruxolitinib; blast phase; combination treatment regimen; myelofibrosis.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow / pathology*
Combined Modality Therapy
Cytarabine / administration & dosage
Fatal Outcome
Female
Humans
Mercaptopurine / administration & dosage
Middle Aged
Nitriles
Primary Myelofibrosis / diagnosis*
Primary Myelofibrosis / drug therapy*
Primary Myelofibrosis / etiology
Pyrazoles / administration & dosage
Pyrimidines
Retreatment
Treatment Outcome

Substances

Nitriles
Pyrazoles
Pyrimidines
Cytarabine
ruxolitinib
Mercaptopurine